ARROWHEAD PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.01 USD | -5.50% |
|
-2.57% | -28.01% |
Presenter SpeechVincent Anzalone (Executives)I think for the last couple of years have been to...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.
Calendar
2024-05-09
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
23.29
USD
Average target price
53.66
USD
Spread / Average Target
+130.42%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -28.01% | 2.89B | |
| -2.08% | 104B | |
| +1.61% | 97.42B | |
| +0.79% | 22.2B | |
| -17.76% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -16.96% | 15.06B | |
| +3.66% | 13.98B | |
| +33.26% | 11.66B |
- Stock Market
- Equities
- ARWR Stock
- News Arrowhead Pharmaceuticals, Inc.
- Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call
